JP2012513411A5 - - Google Patents

Download PDF

Info

Publication number
JP2012513411A5
JP2012513411A5 JP2011542581A JP2011542581A JP2012513411A5 JP 2012513411 A5 JP2012513411 A5 JP 2012513411A5 JP 2011542581 A JP2011542581 A JP 2011542581A JP 2011542581 A JP2011542581 A JP 2011542581A JP 2012513411 A5 JP2012513411 A5 JP 2012513411A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
pharmaceutically acceptable
acceptable salt
activity
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011542581A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012513411A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/069297 external-priority patent/WO2010075443A1/en
Publication of JP2012513411A publication Critical patent/JP2012513411A/ja
Publication of JP2012513411A5 publication Critical patent/JP2012513411A5/ja
Pending legal-status Critical Current

Links

JP2011542581A 2008-12-22 2009-12-22 Ａｋｔの選択的阻害剤およびその使用方法 Pending JP2012513411A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13975308P 2008-12-22 2008-12-22
US61/139,753 2008-12-22
PCT/US2009/069297 WO2010075443A1 (en) 2008-12-22 2009-12-22 Selective inhibitors of akt and methods of using same

Publications (2)

Publication Number Publication Date
JP2012513411A JP2012513411A (ja) 2012-06-14
JP2012513411A5 true JP2012513411A5 (enExample) 2013-06-06

Family

ID=42288129

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011542581A Pending JP2012513411A (ja) 2008-12-22 2009-12-22 Ａｋｔの選択的阻害剤およびその使用方法

Country Status (4)

Country Link
US (1) US20100168162A1 (enExample)
EP (1) EP2381779A4 (enExample)
JP (1) JP2012513411A (enExample)
WO (1) WO2010075443A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103509009A (zh) * 2012-06-21 2014-01-15 中国科学院上海药物研究所 2-取代-5-苯基呋喃类化合物、其制备方法、药物组合物及其用途
US10577349B2 (en) 2015-03-02 2020-03-03 Sanford Burnham Prebys Medical Discovery Institute Quinolinones as inhibitors of translation initiation complex
CN119390701B (zh) * 2024-10-29 2025-11-25 中国药科大学 一种靶向降解pi3k蛋白的化合物及其制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1404329A4 (en) * 2001-06-04 2006-11-02 Cytovia Inc QUINOLINONES 4-ARYL-3- (3-ARYL-1-OXO-2-PROPENYL) -2 (1H) -US SUBSTITUTED, AND ANALOGUES AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS, AND RELATIVE USE
US6998391B2 (en) * 2002-02-07 2006-02-14 Supergen.Inc. Method for treating diseases associated with abnormal kinase activity
US20040171062A1 (en) * 2002-02-28 2004-09-02 Plexxikon, Inc. Methods for the design of molecular scaffolds and ligands
AU2004233828B2 (en) * 2003-04-24 2009-05-28 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
JP4823914B2 (ja) * 2003-11-07 2011-11-24 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Ｆｇｆｒ３の阻害および多発性骨髄腫の治療
WO2005113762A1 (en) * 2004-05-18 2005-12-01 Pfizer Products Inc. CRYSTAL STRUCTURE OF PROTEIN KINASE B-α (AKT-1) AND USES THEREOF
JP2008538102A (ja) * 2005-03-03 2008-10-09 ザ バーナム インスティテュート フォー メディカル リサーチ バーチャルドッキングアプローチを適用したプロテインキナーゼｂ阻害剤のスクリーニング方法並びにそれにより見出された化合物及び組成物

Similar Documents

Publication Publication Date Title
JP2009298801A5 (enExample)
Bigaud et al. Second generation S1P pathway modulators: research strategies and clinical developments
JP2019519519A5 (enExample)
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
FI3721882T3 (fi) Aineenvaihduntahäiriöiden hoito hevoseläimissä
BR112012019374A2 (pt) composição farmacêutica, pellet de liberação prolongada, composição farmacêutica oral, método para tratamento de uma doença neurodegenerativa ou um dano ao sistema nervoso em um indivíduo necessitado do mesmo e método para preparação de uma formulação de liberação prolongada de um agente ativo
JP2016536286A5 (enExample)
JP2013067643A5 (enExample)
RU2016105581A (ru) Способ лечения острого, хронического и подострого кашля и непреодолимого желания откашляться
JP2016539921A5 (enExample)
BRPI0807285A2 (pt) "composição, método para preparar composição farmacêutica, forma unitária de dosagem, método para admnistrar um agente biologicamente ativo a um animal necessitando o agente, método para aumentar a biodisponibilidade de um agente biologicamente ativo, método para preparar uma composição e composto"
BR112012002246A2 (pt) composto, composto ou sal farmaceutico aceitavel deste, composição farmaceutica, metodo para inibir, tratar e/ou reduzir o declinio cognitivol e/ou doença de akzhmer em um paciente
JP2014533272A5 (enExample)
EP2478901A3 (en) Neurogenic compounds
JP2015513396A5 (enExample)
JP2008535785A5 (enExample)
CA2986891C (en) Compositions for use in treating parkinson's disease and related disorders
SI2453923T1 (sl) S peptidi posredovana ne-kovalentna dostava aktivnih učinkovin preko krvno možganske bariere
JP2016513124A5 (enExample)
WO2014052780A3 (en) Compositions and methods of use of an inappetance-controlling compound
MX341660B (es) Agonista del receptor de ghrelina para el tratamiento de caquexia.
MX2013006353A (es) Metodos y composiciones utiles para promover el sueño en animales.
JP2017516842A5 (enExample)
JP2015524474A5 (enExample)
EP4548924A3 (en) Enhanced delivery of drugs and other compounds to the brain and other tissues